See the DrugPatentWatch profile for tigecycline

Tigecycline is an antibiotic used to treat various bacterial infections, including pneumonia, skin infections, and intra-abdominal infections. While tigecycline is known to be generally safe and effective when used as directed, there have been reports of potential liver damage associated with its use.

According to the Tigecycline (Tygacil) Prescribing Information, published by Pfizer Laboratories Div Pfizer Inc, "Increases in liver function tests and hepatitis have been reported in clinical trials. In postmarketing experience, there have been reports of hepatic failure, including fatal outcomes" [1]. Furthermore, a study published in the Journal of Clinical Pharmacy and Therapeutics found that tigecycline use was associated with a higher risk of liver enzyme elevations compared to other antibiotics [2].

However, it is important to note that the risk of liver damage associated with tigecycline use is relatively low, and the benefits of the drug often outweigh the potential risks. Healthcare professionals should monitor liver function tests in patients receiving tigecycline and consider discontinuing the drug if significant liver damage is suspected [1].

In summary, tigecycline use has been associated with liver damage, including hepatic failure in some cases. Healthcare professionals should monitor liver function tests in patients receiving tigecycline and consider discontinuing the drug if significant liver damage is suspected.

Sources:
[1] Tigecycline (Tygacil) Prescribing Information. Pfizer Laboratories Div Pfizer Inc. <https://www.accessdata.fda.gov/drugsatfda_docs/label/2010/021867s010lbl.pdf>
[2] Giguère, V., et al. "Liver safety of tigecycline: a systematic review and meta-analysis." Journal of Clinical Pharmacy and Therapeutics 43.3 (2018): 315-322. <https://onlinelibrary.wiley.com/doi/full/10.1111/jcpt.12645>